{"disease":{"id":"relapsed-or-refractory-b-cell-non-hodgkin-s-lymphoma","name":"relapsed or refractory b cell non hodgkin s lymphoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03245905","title":"Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07523555","title":"Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT04609241","title":"CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":72,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT03263637","title":"Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05370430","title":"BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"PeproMene Bio, Inc.","has_results":false},{"nct_id":"NCT03456726","title":"Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":true},{"nct_id":"NCT03985189","title":"Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Kyowa Kirin Co., Ltd.","has_results":false},{"nct_id":"NCT03664635","title":"MB-CART20.1 Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Miltenyi Biomedicine GmbH","has_results":false},{"nct_id":"NCT05054257","title":"CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Institute of Hematology and Blood Transfusion, Czech Republic","has_results":false},{"nct_id":"NCT03009344","title":"A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":true}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}